

11/29/2006 3:38:33 PM

11/29/2006 4:11:48 PM

[File 344] Chinese Patents Abs Jan 1985-2006/Jan

[File 347] JAPIO Nov 1976-2005/Sep(Updated 060103)

[File 350] Derwent WPIX 1963-2006/UD,UM &UP=200607

[File 371] French Patents 1961-2002/BOPI 200209

Set	Items	Description
S1	61434	S MAGNETIC(3N)RESONA???? OR MRI OR M()R()I OR MAGNETIC()RESONANCE()IMAG???? OR (MR OR M()R) (3N)IMAG???? OR MAGNETIC(2N)IMAG???? OR NMR OR N()M()R OR NUCLEAR()MAGNETIC OR FTNMR OR F()T()N()M()R OR FTMRI OR MAGNETORESONA???? OR PMR OR P()M()R OR PROTON()MAGNETIC()RESONA???? OR PARAMAGNETIC(3N)RESONA???? OR MAGNETIC(3N)RELAX???? OR FERROMAGNETIC(3N)RESONA???? OR MAGNETIC(3N)(SPECTRO????) OR MRA OR M()R()A OR MAGNETIC()RESONANCE()ANGIOGRAPH???? OR CSI OR C()S()I OR CHEMICAL()SHIFT()IMAG???? OR EPR OR E()P()R OR ELECTRON()PARAMAGNETIC()RESONANCE OR FMRI OR F()M()R()I OR FUNCTION????(2N)IMAG???
S2	101975	S (ANALY???? OR INVESTIGAT???? OR EVALUAT???? OR REPORT???? OR STUD???? OR MONITOR????) (3N) (EFFECT???? OR EFFICIEN???? OR CAPAB???? OR COGEN???? OR PERFORM???? OR POTEN???? OR STRENGTH????)
S3	123311	S (PHARMACEUTIC???? OR MEDIC???? OR DRUG OR DRUGS OR NARCOTIC???? OR PRESCRIPTION) (3N) (PREPAR???? OR MANUFACTUR???? OR PRODUC???? OR CREAT???? OR MAKING OR FABRIC????)
S4	13355	S NEURON???? OR NEURON????(3N) (STRUCTURE? ? OR AREA? ? OR REGION???? OR ACTIVIT????)
S5	292245	S (MEASUR???? OR EVALUAT???? OR EXPOS???? OR INDICAT???? OR ANALY???? OR ASSESS???? OR MONITOR???? OR DETERMIN???? OR SENS???? OR DETECT????) (3N) (SIGNAL???? PULS???? OR DATA)
S6	129129	S STATISTIC???? OR CORRELAT???? OR (STATISTIC???? OR CORRELAT???? OR REGRESS???? OR QUANTITATIVE???? OR NUMERIC??? OR COMPUTATION????) (3N) (VARIABLE OR EXPRESSION OR FORMULA???? OR EQUATION)
S7	5175701	S (RECORD??? OR NONVOLATILE OR NON()VOLATILE? ?) (3N) (ELEMENT??? OR DEVICE? ? OR APPARATUS? OR METHOD? ?) OR DISK???? OR DISC???? OR RECORD???? OR SCRIB??? OR READ???? OR WRIT???? OR MEMOR???? OR CACH???? OR BUFFER???? OR CD()ROM OR CD OR COMPACT() (DISC??? OR DISK???) OR RAM? ? OR DRAM? ? OR NVRAM? ? OR SRAM? ? OR SDRAM? ? OR ROM? ? OR PROM? ? OR EPROM? ? OR EEPROM? ? OR STOR????(3N) (DEVICE? ? OR MEANS OR APPARATUS? OR (READ??? OR DATA? ? OR WRIT???? OR RECORD???? OR INFORMATION? ? OR INFO? ? OR COMPUT????) (3N) (STOR??? OR MEMOR???? OR MEDIA OR MEDIUM)
S8	2151180	S PROGRAM???? OR APPLICATION OR ALGORITHM OR LOGIC OR SEQUENC???? OR INSTRUCT???? OR SOFTWARE
S9	51082	S IC=(G06F-019/00)
S10	21533	S MC=(T01-J)
S11	0	S S1 AND S2 AND S3 AND S4 AND S5 AND S6 AND S7 AND S8
S12	1	S S1 AND S2 AND S3 AND S4
S13	0	S (S1(3N)S3)AND S4
S14	43	S S1(3N)S3
S15	22	S S1 AND S3 AND S4
S16	2	S S15 AND S5
S17	2	S S14 AND S2
S18	5	S S14 AND S5
S19	0	S S14 AND S6
S20	8	S S14 AND S7
S22	4	S S15 AND S6
S23	10	S S15 AND S7
S24	4	S S23 AND S8
S25	1	S S15 AND S9
S26	1	S S15 AND S10
S27	2	S S16 NOT S12
S28	2	S S17 NOT (S12 OR S16)
S29	4	S S18 NOT (S12 OR S16 OR S17)
S30	8	S S20 NOT (S12 OR S16 OR S17 AND S18)
S31	1	S S21 NOT (S12 OR S16 OR S17 AND S18 OR S20)
S32	1	S S22 NOT (S12 OR S16 OR S17 AND S18 OR S20 OR S21)
S33	1	S S24 NOT (S12 OR S16 OR S17 AND S18 OR S20 OR S21 OR S22)
S34	0	S S25 NOT (S12 OR S16 OR S17 AND S18 OR S20 OR S21 OR S22 OR S24)
S35	0	S S26 NOT (S12 OR S16 OR S17 AND S18 OR S20 OR S21 OR S22 OR S24 OR S25)

11/29/2006 1:58:02 PM

11/29/2006 3:09:46 PM

[File 2] INSPEC 1898-2006/Feb W3
 [File 155] MEDLINE(R) 1951-2006/Feb 27
 [File 5] Biosis Previews(R) 1969-2006/Feb W3
 [File 6] NTIS 1964-2006/Feb W1 DSSSSSSS
 [File 8] Ei Compendex(R) 1970-2006/Feb W3
 [File 73] EMBASE 1974-2006/Feb 27 [File 94] JICST-EPlus 1985-2006/Dec W1
 [File 94] JICST-EPlus 1985-2006/Dec W2
 [File 95] TEME-Technology & Management 1989-2006/Feb W4
 [File 35] Dissertation Abs Online 1861-2006/Feb
 [File 144] Pascal 1973-2006/Feb W1
 [File 99] Wilson Appl. Sci & Tech Abs 1983-2006/Jan
 [File 34] SciSearch(R) Cited Ref Sci 1990-2006/Feb W3
 [File 434] SciSearch(R) Cited Ref Sci 1974-1989/Dec
 [File 65] Inside Conferences 1993-2006/Feb W4
 [File 162] Global Health 1983-2006/Jan
 [File 164] Allied & Complementary Medicine 1984-2006/Feb
 [File 357] Derwent Biotech Res. 1982-2006/Feb W4
 [File 23] CSA Technology Research Database 1963-2006/Feb
 [File 60] ANTE: Abstracts in New Tech & Engineer 1966-2006/Feb
 [File 294] ONTAP(R) SciSearch(R) Cited Ref Science
 [File 256] TecInfoSource 82-2006/Feb (c) 2006 Info.Sources Inc
 [File 987] TULSA (Petroleum Abs) 1965-2006/Feb W2
 [File 105] AESIS 1851-2001/Jul
 [File 103] Energy SciTec 1974-2006/Feb B2
 [File 58] GeoArchive 1974-2005/Jun
 [File 292] GEOBASE(TM) 1980-2006/Feb W4
 [File 89] GeoRef 1785-2006/Feb B2
 [File 239] Mathsci 1940-2006/Apr
 [File 56] Computer and Information Systems Abstracts 1966-2006/Aug

Set	Items	Description
-----	-------	-------------

S1	2620132	S MAGNETIC(3N) RESONA???? OR MRI OR M()R()I OR MAGNETIC() RESONANCE() IMAG???? OR (MR' OR M()R) (3N) IMAG???? OR MAGNETIC(2N) IMAG???? OR NMR OR N()M()R OR NUCLEAR() MAGNETIC OR FTNMR OR F()T()N()M()R OR FTMRI OR MAGNETORESONA???? OR PMR OR P()M()R OR PROTON() MAGNETIC() RESONA???? OR PARAMAGNETIC(3N) RESONA???? OR MAGNETIC(3N) RELAX???? OR FERROMAGNETIC(3N) RESONA???? OR MAGNETIC(3N) (SPECTRO????) OR MRA OR M()R()A OR MAGNETIC() RESONANCE() ANGIOGRAPH???? OR CSI OR C()S()I OR CHEMICAL() SHIFT() IMAG???? OR EPR OR E()P()R OR ELECTRON() PARAMAGNETIC() RESONANCE OR FMRI OR F()M()R()I OR FUNCTION???? (2N) IMAG???
----	---------	---

S2	6848037	S (ANALY???? OR INVESTIGAT???? OR EVALUAT???? OR REPORT???? OR STUD???? OR MONITOR????) (3N) (EFFECT???? OR EFFICIEN???? OR CAPAB???? OR COGEN???? OR PERFORM???? OR POTEN???? OR STRENGTH????)
----	---------	---

S3	411862	S (PHARMACEUTIC???? OR MEDIC???? OR DRUG OR DRUGS OR NARCOTIC???? OR PRESCRIPTION) (3N) (PREPAR???? OR MANUFACTUR???? OR PRODUC???? OR CREAT???? OR MAKING OR FABRIC????)
----	--------	---

S4	1784909	S NEURON???? OR NEURON???? (3N) (STRUCTURE? ? OR AREA? ? OR REGION???? OR ACTIVIT????)
----	---------	--

S5	2946058	S (MEASUR???? OR EVALUAT???? OR EXPOS???? OR INDICAT???? OR ANALY???? OR ASSESS???? OR MONITOR???? OR DETERMIN???? OR SENS???? OR DETECT????) (3N) (SIGNAL???? PULS???? OR DATA)
----	---------	--

S6	10164370	S STATISTIC???? OR CORRELAT???? OR (STATISTIC???? OR CORRELAT???? OR REGRESS???? OR QUANTITATIVE???? OR NUMERIC??? OR COMPUTATION????) (3N) (VARIABLE OR EXPRESSION OR FORMULA???? OR EQUATION)
----	----------	---

S7	19039779	S (RECORD??? OR NONVOLATILE OR NON() VOLATILE? ?) (3N) (ELEMENT??? OR DEVICE? ? OR APPARATUS? OR METHOD? ?) OR DISK???? OR DISC???? OR RECORD???? OR SCRIB??? OR READ???? OR WRIT???? OR MEMOR???? OR CACH???? OR BUFFER???? OR CD() ROM OR CD OR COMPACT() (DISC??? OR DISK??? OR RAM? ? OR DRAM? ? OR NVRAM? ? OR SRAM? ? OR SDRAM? ? OR ROM? ? OR PROM? ? OR EPROM? ? OR EEPROM? ? OR STOR???? (3N) (DEVICE? ? OR MEANS OR APPARATUS?) OR (READ???? OR DATA? ? OR WRIT???? OR RECORD???? OR INFORMATION? ? OR INFO? ? OR COMPUT????) (3N) (STOR???? OR MEMOR???? OR MEDIA OR MEDIUM)
----	----------	---

10/524000

11/29/2006 1:58:02 PM

11/29/2006 3:09:46 PM

S8 18633454 S PROGRAM????? OR APPLICATION OR ALGORITHM OR LOGIC OR SEQUENC????? OR
INSTRUCT????? OR SOFTWARE

S9 40834 S CC=(A3240 OR A3325 OR A7600 OR A0758 OR A8760I OR B7510N)
S10 0 S S1 AND S2 AND S3 AND S4 AND S4 AND S5 AND S6 AND S7 AND S8
S11 0 S S1 AND S2 AND S3 AND S4 AND S5 AND S6
S12 23 S S1 AND S2 AND S3 AND S4
S13 12 RD (unique items)
S14 1013 S S1(3N)S3
S15 202 S S14 AND S7
S16 47 S S15 AND S8
S17 2 S S16 AND S2
S18 2 RD (unique items)
S19 0 S S14(3N)S4
S20 8 S S14 AND S4
S21 8 RD (unique items)
S22 24 S S1 AND S3 AND S4 AND S6
S23 15 RD (unique items)
S24 5 S S23 AND PY<=2002
S25 108 S S1 AND S3 AND S4
S26 0 S S25 AND (EQUATION(2N)MODEL?????)
S27 4 S S25 AND S5
S28 4 RD (unique items)
S29 10 S S15 AND S5
S30 8 RD (unique items)
S31 3 S S13 AND PY<=2002
S32 2 S S18 NOT S31
S33 8 S S21 NOT (S18 OR S31)
S34 4 S S24 NOT (S18 OR S31 OR S21)
S35 3 S S28 NOT (S18 OR S31 OR S21 OR S24)
S36 8 S S30 NOT (S18 OR S31 OR S21 OR S24 OR S28)

show files

[File 155] **MEDLINE(R)** 1950-2006/Jul 27
(c) format only 2006 Dialog. All rights reserved.

[File 2] **INSPEC** 1898-2006/Jul W3
(c) 2006 Institution of Electrical Engineers. All rights reserved.

[File 5] **Biosis Previews(R)** 1969-2006/Jul W4
(c) 2006 The Thomson Corporation. All rights reserved.

[File 6] **NTIS** 1964-2006/Jul W3
(c) 2006 NTIS, Intl Cpyrght All Rights Res. All rights reserved.

[File 8] **Ei Compendex(R)** 1970-2006/Jul W3
(c) 2006 Elsevier Eng. Info. Inc. All rights reserved.

[File 73] **EMBASE** 1974-2006/Jul 28
(c) 2006 Elsevier Science B.V. All rights reserved.

[File 94] **JICST-EPlus** 1985-2006/Apr W4
(c)2006 Japan Science and Tech Corp(JST). All rights reserved.

[File 35] **Dissertation Abs Online** 1861-2006/Jun
(c) 2006 ProQuest Info&Learning. All rights reserved.

[File 144] **Pascal** 1973-2006/Jul W1
(c) 2006 INIST/CNRS. All rights reserved.

[File 105] **AESIS** 1851-2001/Jul
(c) 2001 Australian Mineral Foundation Inc. All rights reserved.
**File 105: This file is closed (no updates)*

[File 99] **Wilson Appl. Sci & Tech Abs** 1983-2006/Jul
(c) 2006 The HW Wilson Co. All rights reserved.

[File 58] **GeoArchive** 1974-2006/May
(c) 2006 Geosystems. All rights reserved.

[File 34] **SciSearch(R) Cited Ref Sci** 1990-2006/Jul W4
(c) 2006 The Thomson Corp. All rights reserved.

[File 434] **SciSearch(R) Cited Ref Sci** 1974-1989/Dec
(c) 2006 The Thomson Corp. All rights reserved.

[File 292] **GEOBASE(TM)** 1980-2006/Jul W3
(c) 2006 Elsevier Science Ltd. All rights reserved.

[File 89] **GeoRef** 1785-2006/Jul B1
(c) 2006 American Geological Institute. All rights reserved.

[File 65] **Inside Conferences** 1993-2006/Jul 27
(c) 2006 BLDSC all rts. reserv. All rights reserved.

[File 360] **Specialty Chemicals Update Program** 2000/Q2
(c) 2000 SRI International. All rights reserved.

**File 360: Full fmts cost \$85.00 each for TYPEs, DISPLAYs, & PRINTs. Fmt 7 costs \$50.00. SCUP subscribers - use F960. Updating suspended.*

[File 239] **Mathsci** 1940-2006/Sep
(c) 2006 American Mathematical Society. All rights reserved.

[File 347] **JAPIO** Dec 1976-2005/Dec(Updated 060404)
(c) 2006 JPO & JAPIO. All rights reserved.

[File 305] **Analytical Abstracts** 1980-2006/Jul W3
(c) 2006 Royal Soc Chemistry. All rights reserved.

**File 305: Alert feature enhanced for multiple files, duplicate removal, customized scheduling. See HELP ALERT.*

[File 350] **Derwent WPIX** 1963-2006/UD=200647
(c) 2006 The Thomson Corporation. All rights reserved.

**File 350: DWPI has been enhanced to extend content and functionality of the database. For more info, visit <http://www.dialog.com/dwpi/>.*

[File 162] **Global Health** 1983-2006/Jun
(c) 2006 CAB International. All rights reserved.

[File 164] **Allied & Complementary Medicine** 1984-2006/Jul
(c) 2006 BLHCIS. All rights reserved.

[File 357] **Derwent Biotech Res.** _1982-2006/Jul W4
(c) 2006 The Thomson Corp. All rights reserved.

[File 315] **ChemEng & Biotec Abs** 1970-2006/Jun
(c) 2006 DECHEMA. All rights reserved.

[File 23] **CSA Technology Research Database** 1963-2006/Jul
(c) 2006 CSA. All rights reserved.

[File 46] **Corrosion Abstracts** 1966-2006/Jul
(c) 2006 CSA. All rights reserved.

[File 68] **Solid State & Superconductivity Abstracts** 1966-2006/Jul
(c) 2006 CSA. All rights reserved.

[File 60] **ANTE: Abstracts in New Tech & Engineer** 1966-2006/Jul
(c) 2006 CSA. All rights reserved.

[File 33] **Aluminium Industry Abstracts** 1966-2006/Jul

(c) 2006 CSA. All rights reserved.

[File 335] Ceramic Abstracts/World Ceramics Abstracts 1966-2006/Jul

(c) 2006 CSA. All rights reserved.

[File 294] ONTAP(R) SciSearch(R) Cited Ref Science

(c) 2006 The Thomson Corp. All rights reserved.

```
? d s
Set      Items  Description
S1        812   S AU=(DECO G? OR DECO G? OR GALM N? OR GALM, N? OR STETTER M? OR STETTER,
M?)
S2    2042599   S MRI OR MAGNETIC(1W) (IMAG? OR IMAGING) OR MAGNETIC(W) RESONAN? OR NMR OR
NUCLEAR() MAGNETIC() RESONANCE OR FTNMR OR FTMRI
S3    188513    S MAGNETORESONANCE OR PMR OR PROTON(W) MAGNETIC(W) RESONAN? OR MR() (IMAGE?
OR IMAGING)
S4        8409   S MC=(S01-E02A2 OR S03-E07A OR S01-E02A8A OR S01-E02A1 OR S03-E07C OR
S05-D02B1 OR S03-C02F1)
S5        50357   S IC=(G01N-024/08 OR G01V-003/A75 OR G01R-033/56F OR G01V-003/00)
S6        24779   S CC=(A0758 OR A8760I OR B7510N)
S7        2118672 S S2:S6
S8    17601018   S PHARMACEUTICAL OR PHARMACY OR DRUG OR MEDICATION OR MEDICINE? ?
S9    3561743    S PREPARATION? OR MEDICAMENT?
S10   4802615    S NEURONAL OR NERVE OR NEURON OR BRAIN? ?
S11   4277834    S STATIST??????
S12   240892     S CORRELATION(3N) VARIAB???? OR STRUCTURAL(3N) (FORMULA OR EXPRESSION OR
CALCULATION OR COMPUTATION OR EQUATION OR ALGORITHM? OR MODEL???????)
S13    20902     S BLOOD(3N) OXYGENAT?
S14   133955     S S8(2N) S9
S15    4094      S S14 AND S10
S16        6     S S15 AND S12
S17        6     RD (unique items)
S18   1263      S S14 AND S7
S19        1     S S18 AND S1
S20        5     S S17 NOT S19
S21       95     S S18 AND S10
S22       94     S S21 NOT S17
S23        8     S S22 AND CORRELAT?
S24        4     RD (unique items)
S25   172       S S12 AND S14
S26        6     S S10 AND S25
S27        0     S S26 NOT S17
S28        7     S S25 AND CORRELAT?
S29        7     S S28 NOT S17
```

24/3,K/4 (Item 1 from file: 73) [Links](#)

Fulltext available through: [Ex Libris](#) [USPTO Full Text Retrieval Options](#)

EMBASE

(c) 2006 Elsevier Science B.V. All rights reserved.

07160028 EMBASE No: 1998032938

Indirect spectrophotometric determination of thiamine in pharmaceutical preparations

Srividya K.; Balasubramanian N.

K. Srividya, Department of Chemistry, Indian Institute of Technology, Chennai-600 036 India

Chemical and Pharmaceutical Bulletin (CHEM. PHARM. BULL.) (Japan) 1997 , 45/12 (2100-2103)

CODEN: CPBTA ISSN: 0009-2363

Document Type: Journal ; Article

Language: ENGLISH Summary Language: ENGLISH

Number Of References: 24

Indirect spectrophotometric determination of thiamine in pharmaceutical preparations

...found to decrease linearly with increasing concentrations of thiamine, which is corroborated by the calculated correlation coefficient value of -0.998. The system obeys Beer's law for 0-25µg of... ..n=10), respectively. The proposed method was applied successfully to the determination of thiamine in pharmaceutical preparations. The reliability of the assay was established by parallel determination by the standard thiochrome method...

MEDICAL DESCRIPTORS:

anorexia; cardiomegaly; muscle weakness; nerve degeneration; titrimetry; spectrofluorometry; spectrophotometry; chemoluminescence; atomic absorption spectrometry; nuclear magnetic resonance; atomic emission spectrometry; reliability; calculation; reproducibility; article

t 29/3,k/all

29/3,K/1 (Item 1 from file: 155) [Links](#)

Fulltext available through: [Ex Libris](#) [USPTO Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2006 Dialog. All rights reserved.

14870118 **PMID:** 15124206

Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds.

Yamazaki Kazuto; Kanaoka Masaharu

Sumitomo Pharmaceuticals Co., Ltd., 1-98, Kasugade Naka 3-Chome, Konohana-ku, Osaka, 554-0022, Japan.

kanaoka@sumitomopharm.co.jp

Journal of pharmaceutical sciences (United States) Jun 2004 , 93 (6) p1480-94 , ISSN: 0022-3549--Print

Journal Code: 2985195R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...binding percent data. These drugs were classified according to protonation state and pharmacophore features. The **correlation** formula for each class is a simple sigmoidal function of variable LogP or LogD. A **correlation** formula of variable LogD at pH 7.4 with a good **correlation** coefficient (R-squared = 0.803) was obtained for neutral and basic drugs, with the exception of zwitterions. A **correlation** formula using LogP as variable for acidic drugs with one of the specific pharmacophore features gave a good **correlation** coefficient (R-squared = 0.786). The method was verified using the protein binding data of... compounds that had not been included in the data set to configure the formulas. The **correlation** coefficient (R-squared) between the experimental and predicted protein binding percent was 0.830. In...

Descriptors: *Blood Proteins--metabolism--ME; *Computational Biology--methods--MT; * **Pharmaceutical Preparations**--metabolism--ME ; Blood Proteins--chemistry--CH; **Pharmaceutical Preparations** --chemistry--CH; Predictive Value of Tests; Protein Binding--physiology--PH

Chemical Name: Blood Proteins; **Pharmaceutical Preparations**

29/3,K/2 (Item 2 from file: 155) [Links](#)

Fulltext available through: [Ex Libris](#) [USPTO Full Text Retrieval Options](#)

MEDLINE(R)

(c) format only 2006 Dialog. All rights reserved.

14797187 PMID: 15033093

[Do we spend too much on medications? Pharmaceutical expenditures, an absolutely essential item in European countries.]

'Gastamos demasiado en medicamentos? El gasto farmaceutico, un bien de primera necesidad entre los paises europeos.

Simo Minan J; de Pablo Gonzalez R; Ramos Maestre M J; Gaztambide Ganuza M S

Medico Especialista en Medicina Familiar y Comunitaria, Centro de Salud ALTABIX, Elche, Alicante, Espana. ju.simon@coma.es

Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria (Spain) Mar 31 2004 , 33 (5) p244-53 , ISSN: 0212-6567--Print Journal Code: 9111075

Publishing Model Print

Document type: Journal Article ; English Abstract

Languages: SPANISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...other variables as expenditure on health, on research and development (R&D), and socio-demographic **variables** are analysed with **correlation** and multiple linear regression. RESULTS: In both groups of countries, the Gross Domestic Product per capita (GDPPC) is positively and significantly **correlated** with the expenditure per capita on health (public and total) and on R&D, but... ..on health (PhE/TE) or as percentage of GDP (PhE/GDP), is negatively and significantly **correlated** with income (GDPPC). The regression model accepts as explicative variables of PhE/GDP: the income...

Descriptors: *Drug Costs; *Fees, Pharmaceutical; *Models, Econometric; * **Pharmaceutical**

Preparations--economics--EC

Chemical Name: Pharmaceutical Preparations

29/3,K/3 (Item 3 from file: 155) [Links](#)

Fulltext available through: [Ex Libris](#) [USPTO Full Text Retrieval Options](#)

MEDLINE(R)

(c) format only 2006 Dialog. All rights reserved.

12465871 **PMID:** 10407257

A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption.

Dunne A; O'Hara T; Devane J

Department of Statistics, University College Dublin, Dublin 4, Ireland.

Statistics in medicine (ENGLAND) Jul 30 1999 , 18 (14) p1865-76; discussion 1877 , ISSN: 0277-6715--Print

Journal Code: 8215016

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...absorption) in vivo and that in vitro is known as an 'in vitro-in vivo **correlation**' (IVIVC) whose importance stems from the fact that it may be used to minimize the... component which describes a time varying relationship.

Following the addition of random effects to these **structural models** in order to account for the repeated measures nature of the data collected, the models...

Descriptors: *Models, Biological; *Models, Statistical; ***Pharmaceutical Preparations**--administration and dosage--AD

Chemical Name: Delayed-Action Preparations; **Pharmaceutical Preparations**

29/3,K/4 (Item 4 from file: 155) [Links](#)

Fulltext available through: [Ex Libris](#) [USPTO Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2006 Dialog. All rights reserved.

10268155 **PMID:** 7806423

Determinants of drug removal by continuous hemofiltration.

Lau A H; Kronfol N O

Department of Pharmacy Practice, University of Illinois at Chicago.

International journal of artificial organs (ITALY) Jul 1994 , 17 (7) p373-8 , ISSN: 0391-3988--Print **Journal**
Code: 7802649

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...were generally higher than those obtained with blood. Molecular weights of the drugs did not **correlate** with the magnitude of drug sieving. Sieving coefficients in blood were also predicted from saline...

Descriptors: *Hemofiltration; ***Pharmaceutical Preparations** ; Animals; Anti-Bacterial Agents--blood--BL; Anticonvulsants--blood--BL; Cattle; Digoxin--blood--BL; Membranes, Artificial; **Models, Structural**; Theophylline--blood--BL

Chemical Name: Anti-Bacterial Agents; Anticonvulsants; **Pharmaceutical Preparations**; Digoxin; Theophylline

29/3,K/5 (Item 5 from file: 155) [Links](#)

Fulltext available through: [Ex Libris](#) [USPTO Full Text Retrieval Options](#)

MEDLINE(R)

(c) format only 2006 Dialog. All rights reserved.

10215756 PMID: 7959448

Modelling of human acute toxicity from physicochemical properties and non-vertebrate acute toxicity of the 38 organic chemicals of the MEIC priority list by PLS regression and neural network.

Calleja M C; Geladi P; Persoone G

Laboratory for Biological Research in Aquatic Pollution, University of Ghent, Belgium.

Food and chemical toxicology - an international journal published for the British Industrial Biological Research

Association (ENGLAND) Oct 1994 , 32 (10) p923-41 , ISSN: 0278-6915--Print **Journal Code: 8207483**

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...and neural network were utilized. A neural network using a combination of backpropagation and cascade-**correlation** algorithms was applied in this study. The results generally reveal a slightly better predictive performance... ...with pruning technique proved superior to that trained with a combination of backpropagation and cascade-**correlation** algorithms after leave-one-out cross-validation. The predictive power of the PC-models, whether linear or non-linear, was comparable with that of the corresponding **models** consisting of both **structural** descriptors and the ecotoxicological tests (ECOPC-models), except for the battery (ECOPC-model) from the...
; ...Dose 50; Linear Models; Magnetic Resonance Spectroscopy; Models, Biological; Neural Networks (Computer); Pesticides--chemistry--CH; **Pharmaceutical Preparations**--chemistry--CH; Photobacterium; Regression Analysis; Research Support, Non-U.S. Gov't; Rotifera; Solvents --chemistry...

Chemical Name: Pesticides; **Pharmaceutical Preparations**; Solvents

29/3,K/6 (Item 6 from file: 155) [Links](#)

Fulltext available through: [Ex Libris](#) [USPTO Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2006 Dialog. All rights reserved.

09752537 **PMID:** 8377088

Factorial design-based optimization of the formulation of isosorbide-5-mononitrate microcapsules.

Farivar M; Kas H S; Oner L; Hincal A A

Pharmaceutical Technology Department, Pharmacy Faculty, Hacettepe University, Ankara, Turkey.

Journal of microencapsulation (ENGLAND) Jul-Sep 1993 , 10 (3) p309-17 , ISSN: 0265-2048--Print **Journal**

Code: 8500513

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...dependent variable, t50 percent is investigated by the second-order polynomial equation to establish the **correlation** between independent **variables**. By using the calculated equations, the response-surface graphs, from which various levels of independent...

; Delayed-Action **Preparations**; **Drug** Design; Isosorbide Dinitrate--administration and dosage--AD; Isosorbide Dinitrate--chemistry --CH; Particle Size; Research Support...

29/3,K/7 (Item 1 from file: 305) [Links](#)

Fulltext available through: [Ex Libris](#) [USPTO Full Text Retrieval Options](#)

Analytical Abstracts

(c) 2006 Royal Soc Chemistry. All rights reserved.

276134 AA Accession No.: 60-08-G-00151 Doc. Type: Journal

Calibration in near-infra-red diffuse reflectance spectroscopy. A comparative study of various methods.

Author: Blanco, M. ; Coello, J. ; Iturriaga, H. ; Maspoch, S. ; de la Pezuela, C.

Corporate Source: Dept. Quim., Univ. Autonoma de Barcelona, 08193 Bellaterra, Barcelona, Spain

Journal: J. Near Infrared Spectrosc. , (JOURNAL OF NEAR INFRARED SPECTROSCOPY), Volume: 5, Issue: 2, Pages: 67-75

CODEN: JNISEI **ISSN:** 0967-0335

Publication Date: 1997 (970000) **Language:** English

Abstract: ...model, consecutive PC were used beginning with that containing the largest eigenvalue. In the PCR correlation criterion model the PC showing the highest correlation with the response variable were used. In the PCR-best subset criterion model, the PC providing the lowest predicted...

Matrix: pharmaceutical preparations...

22/9/8 (Item 3 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rights reserved.

0014449725 Biosis No.: 200300408444

Experimental model for functional magnetic resonance imaging of somatic sensory cortex in the unanesthetized rat.

Author: Sachdev Robert N S; Champney Greg C; Lee Haakil; Price Ronald R; Pickens David R; Morgan Victoria L; Stefansic James D; Melzer Peter (Reprint); Ebner Ford F

Author Address: Department of Psychology, Vanderbilt University, 111 21st/Ave., 301 Wilson Hall, South, Nashville, TN, 37203, USA**USA

Author E-mail Address: Peter.Melzer@Vanderbilt.edu

Journal: NeuroImage 19 (3); p 742-750 July 2003 2003

Medium: print

ISSN: 1053-8119 _(ISSN print)

Document Type: Article

Record Type: Abstract

Language: English

Abstract: Functional magnetic resonance imaging (fMRI) has evolved into a method widely used to map neural activation in the human brain. fMRI is a method for recording blood oxygen level-dependent (BOLD) signals. These signals change with local cerebral blood flow coupled to neural activity. However, the relationship between BOLD signals and neural function is poorly understood and requires the development of animal models. Here we use an unanesthetized rat preparation to study BOLD responses to whisker stimulation in somatic sensory barrel cortex. Five rats were trained to tolerate restraint in a holder and fMRI noise with positive reinforcement. For maximal immobilization, the head was fastened to the holder with nuts screwed on threaded bolts attached to the head. On scanning day, residual stress was alleviated with injections of diazepam, and the rats were restrained in the holder and transferred into the scanner. After >75 min to allow the tranquilization to abate, structural images were acquired from three coronal brain slices. Subsequently, functional images were taken utilizing 4-min epochs without stimulation alternated with equivalent epochs during which the right caudal whiskers were stimulated with three air puffs/s. After 4 weeks, fMRI could be repeated in four rats. In seven of the nine functional runs, head motion was minimal and whisker stimulation resulted in a statistically significant ($P < 0.05$) increase in BOLD signal in barrel cortex predominantly on the contralateral side. The results provide encouragement that long-term fMRI studies on cerebral function in unanesthetized rats may be feasible with our procedure.

Registry Numbers: 439-14-5: diazepam

Descriptors:

Major Concepts: Methods and Techniques; Nervous System--Neural Coordination

Biosystematic Names: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

Organisms: rat (Muridae)

Organisms: Parts Etc: brain--nervous system; somatic sensory barrel cortex--nervous system ; somatic sensory cortex--nervous system; whisker--integumentary system

Common Taxonomic Terms: Animals; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman Mammals; Rodents; Vertebrates

Chemicals & Biochemicals: diazepam--autonomic-drug

Methods & Equipment: functional magnetic resonance imaging--clinical techniques, diagnostic techniques,

imaging and microscopy techniques, laboratory techniques

Miscellaneous Terms: blood oxygen level-dependent signal; cerebral blood flow; head motion; residual stress

Concept Codes:

10060 Biochemistry studies - General

12512 Pathology - Therapy

18504 Integumentary system - Physiology and biochemistry

20504 Nervous system - Physiology and biochemistry

22024 Pharmacology - Neuropharmacology

Biosystematic Codes:

86375 Muridae

39/3,K/7 (Item 7 from file: 155) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

MEDLINE(R)

(c) format only 2006 Dialog. All rights reserved.

13867485 PMID: 12162757

Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

de Lange Elizabeth C M; Danhof Meindert

Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden, The Netherlands. l.lange@lacdr.leidenuniv.nl

Clinical pharmacokinetics (New Zealand) 2002 , 41 (10) p691-703 , ISSN: 0312-5963--Print Journal Code: 7606849

Publishing Model Print

Document type: Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

...

...are sometimes used as a surrogate for drug concentrations at the target site within the brain. However, the brain consists of multiple compartments and many factors are involved in the transport of drugs from plasma into the brain and the distribution within the brain. In particular, active transport processes at the level of the blood-brain barrier and blood-CSF barrier, such as those mediated by P-glycoprotein, may lead to complex relationships between concentrations in plasma, ventricular and lumbar CSF, and other brain compartments. Therefore, CSF concentrations may be difficult to interpret and may have limited value. Pharmacokinetic...
...used instead, providing more valuable information. As non-invasive alternative techniques, positron emission tomography or magnetic resonance spectroscopy may be of added value.

Descriptors: *Blood-Brain Barrier--physiology--PH; *Brain--metabolism--ME; *Pharmaceutical Preparations--cerebrospinal fluid--CF; *Pharmacokinetics ; Animals; Biological Transport, Active; Blood-Brain Barrier--drug effects--DE; Cerebrovascular Circulation; Drug Delivery Systems; Humans; Pharmaceutical Preparations--metabolism--ME; Tissue Distribution

Chemical Name: Pharmaceutical Preparations

39/3,K/14 (Item 14 from file: 155) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

MEDLINE(R)

(c) format only 2006 Dialog. All rights reserved.

11537336 PMID: 9370049

Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier.

de Lange E C; Danhof M; de Boer A G; Breimer D D

Leiden/Amsterdam Center for Drug Research, University of Leiden, Netherlands. l.lange@chem.leidenuniv.nl

Brain research. Brain research reviews (NETHERLANDS) Sep 30 1997 , 25 (1) p27-49 , ISSN:

0165-0173--Print Journal Code: 8908638

Publishing Model Print

Document type: Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier.

...

For the study of the pharmacokinetics of drugs in the brain a number of in vivo techniques is available, including autoradiography, imaging techniques, cerebrospinal fluid sampling... ..It permits monitoring of local concentrations of drugs and metabolites at specific sites in the brain which makes it an attractive tool for pharmacokinetic research. In the use of this technique... ..temperature of the perfusion medium. In particular in studies on drug transport across the blood-brain barrier (BBB), effects of insertion of the probe on BBB functionality is important. It appears...

Descriptors: *Blood-Brain Barrier--physiology--PH; *Brain--metabolism--ME;

*Microdialysis--methods--MT; *Pharmaceutical Preparations --metabolism--ME; *Pharmacokinetics ;

Animals; Autoradiography; Humans; Magnetic Resonance Spectroscopy; Tissue Distribution; Tomography, Emission-Computed

Chemical Name: Pharmaceutical Preparations

39/3,K/26 (Item 1 from file: 73) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

EMBASE

(c) 2006 Elsevier Science B.V. All rights reserved.

12932306 EMBASE No: 2004532717

Transient global amnesia following the use of ergots in the treatment of migraine

AMNESIA GLOBAL TRANSITORIA TRAS EL USO DE ERGOTICOS EN LA MIGRAN(tilde)A

Gil-Martinez T.; Galiano R.

Dr. R. Galiano, Unidad de Neurologia, Servicio de Medicina Interna, Hospital General de Requena, Paraje Casablanca, s/n, E-46340 Requena, Valencia Spain

Author Email: galiano raf@gva.es

Revista de Neurologia (REV. NEUROL.) (Spain) 16 NOV 2004 , 39/10 (929-931)

CODEN: RVNRA **ISSN:** 0210-0010

Document Type: Journal ; Article

Language: SPANISH **Summary Language:** ENGLISH; SPANISH; PORTUGUESE

Number Of References: 22

...put forward about its epileptic or ischemic origin, or the relationship that exists with the **neuronal** depression that is produced in migraine. A number of triggering factors have been described, including the taking of distinct **pharmaceutical preparations**. Case report. We report the cases of two patients with a history of migraines who...

MEDICAL DESCRIPTORS:

...vasoconstriction; drug utilization; clinical feature; neurologic examination; electroencephalogram; computer assisted tomography; photophobia; nausea and vomiting; **nuclear magnetic resonance imaging**; human; female; case report; adult; article

Emtree Codes:

39/3,K/27 (Item 2 from file: 73) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

EMBASE

(c) 2006 Elsevier Science B.V. All rights reserved.

07160028 EMBASE No: 1998032938

Indirect spectrophotometric determination of thiamine in pharmaceutical preparations

Srividya K.; Balasubramanian N.

K. Srividya, Department of Chemistry, Indian Institute of Technology, Chennai-600 036 India

Chemical and Pharmaceutical Bulletin (CHEM. PHARM. BULL.) (Japan) 1997 , 45/12 (2100-2103)

CODEN: CPBTA ISSN: 0009-2363

Document Type: Journal ; Article

Language: ENGLISH Summary Language: ENGLISH

Number Of References: 24

Indirect spectrophotometric determination of thiamine in pharmaceutical preparations

...n=10), respectively. The proposed method was applied successfully to the determination of thiamine in pharmaceutical preparations. The reliability of the assay was established by parallel determination by the standard thiochrome method...

MEDICAL DESCRIPTORS:

anorexia; cardiomegaly; muscle weakness; nerve degeneration; titrimetry; spectrofluorometry; spectrophotometry; chemoluminescence; atomic absorption spectrometry; nuclear magnetic resonance; atomic emission spectrometry; reliability; calculation; reproducibility; article

Emtree Codes:

39/3,K/69 (Item 2 from file: 350) [Links](#)

Derwent WPIX

(c) 2006 The Thomson Corporation. All rights reserved.

0014254273

WPI Acc no: 2004-440452/**200441**

Related WPI Acc No: 2004-043119; 2005-046473; 2005-151670; 2006-233642

XRAM Acc no: C2004-165034

XRPX Acc No: N2004-348518

Obtaining a representation of the 3-D structure of cytochrome P450 3A4 crystals, by providing data of structure factors used to generate electron density map of crystal structure and constructing electron density map of obtained data

Patent Assignee: ASTEX TECHNOLOGY LTD (ASTE-N)

Inventor: JHOTI H; JHOTI H A T L; KIRTON S B; TICKLE I J; TICKLE I J A T L; VONRHEIN C; VONRHEIN C G P L; WILLIAMS P A; WILLIAMS P A A T L

Patent Family (8 patents, 105 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2004038015	A1	20040506	WO 2003GB4598	A	20031024	200441	B
GB 2395718	A	20040602	GB 200324870	A	20031024	200441	E
AU 2003274378	A1	20040513	AU 2003274378	A	20031024	200468	E
GB 2395718	B	20050119	GB 200324870	A	20031024	200506	E
GB 2408509	A	20050601	GB 200324870	A	20031024	200536	E
			GB 200427006	A	20041209		
EP 1554380	A1	20050720	EP 2003758362	A	20031024	200547	E
			WO 2003GB4598	A	20031024		
US 20050159901	A1	20050721	WO 2002GB2668	A	20020530	200548	E
			US 2002421063	P	20021025		
			US 2003221036	A	20030115		
			US 2003479448	P	20030619		
			US 2003690991	A	20031023		
			US 200576967	A	20050311		
JP 2006503912	W	20060202	WO 2003GB4598	A	20031024	200611	E
			JP 2005501546	A	20031024		

Priority Applications (no., kind, date): GB 20018214 A 20010402; GB 20018212 A 20010402; US 2002421063 P 20021025; US 2003479448 P 20030619

Patent Details

Patent Number	Kind	Lan	Pgs	Draw	Filing Notes
WO 2004038015	A1	EN	357	3	
National Designated States, Original	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ				

	TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
Regional Designated States,Original	AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
AU 2003274378	A1	EN			Based on OPI patent	WO 2004038015
GB 2408509	A	EN			Division of application	GB 200324870
EP 1554380	A1	EN			PCT Application	WO 2003GB4598
					Based on OPI patent	WO 2004038015
Regional Designated States,Original	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
US 20050159901	A1	EN			C-I-P of application	WO 2002GB2668
					Related to Provisional	US 2002421063
					C-I-P of application	US 2003221036
					Related to Provisional	US 2003479448
					Division of application	US 2003690991
JP 2006503912	W	JA	179		PCT Application	WO 2003GB4598
					Based on OPI patent	WO 2004038015

200441...

Alerting Abstract ... admixing the molecule with a carrier. (M2) or (M5)-(M9) is useful for producing a **medicament, pharmaceutical** composition or drug, which involves identifying molecular structure or modulator by the above-mentioned methods, and preparing a **medicament, pharmaceutical** composition or drug containing the optimized modulator molecule, where the compound or composition is useful...

Technology Focus ...

a model constructed from all or a portion of the coordinates as defined in data **statistics** for the peak wavelength data as given in specification+/-a root mean square deviation from... ... coordinate data of a target P450 protein generated by interpreting X-ray crystallographic data or **NMR** data by reference to the data of F1; structure factor data derivable from the atomic...

The operation could not be performed. An unexpected error has occurred.
(01-242C)

39/3,K/72 (Item 5 from file: 350) [Links](#)

Derwent WPIX

(c) 2006 The Thomson Corporation. All rights reserved.

0012706334 *Drawing available*

WPI Acc no: 2002-557736/**200259**

XRAM Acc no: C2002-158359

New paramagnetic metal-phthalocyanine complex compounds useful e.g. as contrast agents in magnetic resonance imaging

Patent Assignee: KOO K (KOOK-I); LEE S (LEES-I); LEE S Y (LEES-I)

Inventor: KOO G I; KOO K; KOO K Y; LEE S; LEE S Y

Patent Family (9 patents, 97 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2002053570	A1	20020711	WO 2002KR12	A	20020104	200259	B
KR 2002057809	A	20020712	KR 200230	A	20020102	200305	E
EP 1355913	A1	20031029	EP 2002727019	A	20020104	200379	E
			WO 2002KR12	A	20020104		
AU 2002219679	A1	20020716	AU 2002219679	A	20020104	200427	E
CN 1487947	A	20040407	CN 2002804063	A	20020104	200441	E
JP 2004528280	W	20040916	JP 2002555093	A	20020104	200461	E
			WO 2002KR12	A	20020104		
US 20040214810	A1	20041028	WO 2002KR12	A	20020104	200471	E
			US 2003250512	A	20031117		
KR 448100	B	20040914	KR 200230	A	20020102	200508	E
US 7005517	B2	20060228	WO 2002KR12	A	20020104	200616	E
			US 2003250512	A	20031117		

Priority Applications (no., kind, date): KR 2001555 A 20010105; KR 200230 A 20020102

Patent Details

Patent Number	Kind	Lan	Pgs	Draw	Filing Notes	
WO 2002053570	A1	EN	30	6		
National Designated States,Original	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
Regional Designated States,Original	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
EP 1355913	A1	EN			PCT Application	WO 2002KR12
					Based on OPI patent	WO 2002053570

Regional Designated States,Original	AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR															
AU 2002219679	A1		EN			Based on OPI patent						WO 2002053570				
JP 2004528280	W		JA	44		PCT Application						WO 2002KR12				
						Based on OPI patent						WO 2002053570				
US 20040214810	A1		EN			PCT Application						WO 2002KR12				
KR 448100	B		KO			Previously issued patent						KR 2002057809				
US 7005517	B2		EN			PCT Application						WO 2002KR12				
						Based on OPI patent						WO 2002053570				

200259...

New paramagnetic metal-phthalocyanine complex compounds useful e.g. as contrast agents in magnetic resonance imaging

Alerting Abstract ... USE - As contrast agents useful for diagnostic X-ray imaging, computer tomography and **magnetic resonance imaging** (all claimed), to obtain the images of tissues (e.g. blood vessels, tumors) and peripheral... ... **ADVANTAGE** - (I) enhances tissue-specific contrast of MR (**magnetic resonance**) **images**, and tissue-specific diagnostic X-ray imaging and computer tomography, of organs and tissues of... ... the images of organs or cellular tissues of patients when administered into patients while using **magnetic resonance imaging**. (I) shows high imaging enhancement effects at lower concentrations and are safer over the previously... ... agents have good water solubility, the agents are safer and can be made into simple **pharmaceutical preparation** as compared to prior art contrast agents commonly administered into intravenously. Since the contrast agents... ... production cost per unit. By using the contrast agents, the contrast imaging diagnosis such as **magnetic resonance imaging** and X-ray can be carried out more safely and effectively. Due to their small... ... This leads to excessive administration of contrast agents and with respect to scanning time of **magnetic resonance imaging**, the conventional **magnetic resonance imaging** contrast agents are disadvantageous in that the scanning has to be carried out in a... ... of the present invention, there is an advantage of a longer scanning period while using **magnetic resonance imaging**. Moreover, the wash-out time from the tissues is prolonged as compared to the conventional...

Extension Abstract

ADMINISTRATION - For **magnetic resonance imaging**, (I) is administered in a concentration of 0.0001 - 10 mmol/kg, and for X...

Original Publication Data by Authority

...

Original Abstracts:

metal-phthalocyanine complexes and pharmaceutically acceptable salts thereof which are useful as contrast agents for **MRI (Magnetic Resonance Imaging)**, diagnostic X-ray imaging and computed tomography(CT).The present invention also refers to contrast... ... metal-phthalocyanine complexes and pharmaceutically acceptable salts thereof, which are useful as contrast agents for **MRI (Magnetic Resonance Imaging)**, diagnostic X-ray imaging and computed tomography (CT).The present invention also provides contrast agents... ... metal-phthalocyanine complexes and pharmaceutically acceptable salts thereof, which are useful as contrast agents for **MRI(Magnetic Resonance Imaging)**, diagnostic X-ray imaging and computed tomography(CT).The present invention also provides

contrast agents... .. metal-phthalocyanine complexes and pharmaceutically acceptable salts thereof which are useful as contrast agents for **MRI (Magnetic Resonance Imaging)**, diagnostic X-ray imaging and computed tomography(CT).The present invention also refers to contrast...

Claims:

1. A compound having the **structural formula**[C00004]and the pharmaceutically acceptable salts thereof, wherein M is Gd(III) or Mn(II)... .. What is claimed is:1. A compound having the **structural formula**[CF C00004]and the pharmaceutically acceptable salts thereof, wherein M is Gd(III) or Mn...